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Background: Heart failure (HF) is a serious complication of acute coronary syndromes (ACS), and is associated with
high in-hospital mortality and poor long-term survival. The aims of this study were to describe the clinical
characteristics, management and in-hospital outcomes of coronary syndrome (ACS) patients with HF in the United
Arab Emirates.
Findings: The study was selected from the Gulf Registry of Acute Coronary Events (Gulf RACE), a prospective
multi-national, multicenter registry of patients hospitalized with ACS in six Middle East countries. The present analysis
was focused on participants admitted to various hospitals in the UAE with a diagnosis of ACS in 2007 and were
analyzed in terms of HF (Killip class II/III and IV) on admission. Of 1691 patients (mean age: 52.6 ± 11.7 years; 210
Females, 1481 Males) with ACS, 356 (21%) had an admission diagnosis of HF (Killip class II/III and IV). HF patients were
less frequently males (19.2% vs. 34.3%; P< 0.001). HF was more frequently associated with hypertension (64.3% vs.
43.9%; P < 0.001), hyperlipidemia (49.4% vs. 31.8%; P < 0.001) and diabetes mellitus (DM) (51.1% vs. 36.2%; P < 0.001).
HF was significantly associated with in-hospital mortality (OR = 11.821; 95% CI: 5.385-25.948; P < 0.001). In multivariate
logistic regression, age, hyperlipidemia, heart rate and DM were associated with higher in-hospital HF.
Conclusions: HF is observed in about 1 in 5 patients with ACS in the UAE and is associated with a significant
increase in in-hospital mortality and other adverse outcomes.
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Heart failure (HF) is a growing problem that puts a tre-
mendous burden on health care facilities worldwide. Up
to 70% of all patients with HF die within 5 years after
their first hospital admission [1]. The most common
cause of HF is coronary artery disease (CAD), including
the acute coronary syndromes (ACS) of ST-segment ele-
vation myocardial infarction (STEMI), non-STEMI
(NSTEMI), and unstable angina (UA) [2]. The develop-
ment of HF following ACS significantly worsens short-
and long-term prognosis [3]. In developed countries,
CAD is a major cause of HF, morbidity and mortality.* Correspondence: a.shehab@uaeu.ac.ae; bayan.al-dabbagh@uaeu.ac.ae
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reproduction in any medium, provided the orSignificant advances have been made over the last dec-
ade in therapeutic approaches to ACS, particularly the
development of new antiplatelet therapies and recogni-
tion of the benefits of neurohumoral blockade. Nonethe-
less, ACS remains among the main causes of death in
developing countries [3]. One factor contributing to the
poor prognosis is development of HF and left ventricular
dysfunction following myocardial infarction (MI) [4]. It
is of utmost importance to identify patients at risk of
developing HF at admission since it may influence im-
mediate therapeutic choices and subsequent risk stratifi-
cation strategies which consequently help improve
prognosis, personalize patient care, optimize the use of
healthcare resources and prevent HF and death.
The aim of this work was to describe the clinical char-
acteristics, and in-hospital management/outcomes ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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rolled in the Gulf Registry of Acute Coronary Events
(Gulf RACE) [5,6]. We also evaluated HF impact on in-
hospital mortality.
Methods
Patients and data collection
Patients were selected from the Gulf Registry of Acute
Coronary Events (Gulf RACE), a prospective multi-
national, multicentre registry of patients above 18 years
of age hospitalized with the final diagnosis of ACS from
various hospitals in 6 Middle Eastern countries, namely:
Oman, United Arab Emirates (UAE), Qatar, Bahrain, Ku-
wait and Yemen [5]. Details of the Gulf RACE design
and methods have been previously described [5]. There
were no exclusion criteria. The recruitment in the pilot
phase started from May 8, 2006, to June 6, 2006. Enrol-
ment in the next phase of the registry started in January
29, 2007, and continued for 5 months till June 29, 2007.
The present study included 1691 of 1697 patients hospi-
talized with an ACS across 18 hospitals in the UAE with
complete data on HF (with HF: 356, 21.1%). These hos-
pitals care for more than 85% of patients with ACS in
the country. Demographic, historical, and clinical data as
well as in-hospital outcomes were recorded by study
physicians for all patients admitted with a diagnosis
of ACS.
Definitions of the sets of variables collected from the
patients, outcome parameters as well as the diagnosis of
ACS types were done following the American College of
Cardiology (ACC) clinical data standards [7], for example:
1. DM: history of diabetes, regardless of duration of
disease, need for antidiabetic agents, or a fasting
blood sugar greater than 7 mmol/l or 126 mg/dl.
2. Hypertension: documented by: 1. History of
hypertension diagnosed and treated with medication,
diet, and/or exercise, 2. Blood pressure greater than
140 mmHg systolic or 90 mmHg diastolic on at least
2 occasions and 3. Current use of antihypertensive
pharmacological therapy.
3. Hyperlipidemia: diagnosed and/or treated by a
physician. National Cholesterol Education Program
criteria include documentation of the following: 1.
Total cholesterol greater than 200 mg/dl (5.18 mmol/l);
or 2. Low-density lipoprotein (LDL) greater than or
equal to 130 mg/dl (3.37 mmol/l); or 3. High-density
lipoprotein (HDL) less than 40 mg/dl (1.04 mmol/l).
Treatment is also initiated if LDL is greater than
100 mg/dl (2.59 mmol/l) in patients with known
coronary artery disease, and this would qualify as
hypercholesterolemia.
4. Past revascularization: including CABG or PCI of
any type (balloon angioplasty, atherectomy, stent, orother) done before the current admission with the
dates noted.
5. Prior CAD: includes history of angina before the
current admission and if it existed more than
2 weeks before admission and/or within 2 weeks
before admission. “Angina” refers to evidence or
knowledge of symptoms before this acute event
described as chest pain or pressure, jaw pain, arm
pain, or other equivalent discomfort suggestive of
cardiac ischemia. MI: the patient at least had 1
documented previous MI before admission with the
date noted.
All the patients were assigned to one of the following ca-
tegories: ST-elevation myocardial infarction (STEMI), non-
ST-segment elevation myocardial infarction (NSTEMI), left
bundle branch block myocardial infarction (LBB MI) and
UA. These definitions take into account clinical presenta-
tion, ECG findings, and the results of serum biochemical
markers of myocardial necrosis (troponin and CPK-MB).
Following ACS incidents after admissions, serial of cardiac
enzymes were recorded and the highest (peak) values were
used in our paper. Particularly, UA was defined as ACS
with normal biochemical markers of necrosis. Patients
were categorized at the time of hospital admission
according to the classification of Killip and Kimball [8]
for signs of HF. Killip class (scale I–IV) is a risk stra-
tification tool for patients after acute myocardial
infarction (AMI); a low Killip class indicates a lower
likelihood of death within the first 30 days than a high
Killip class. Smokers were defined as smoking ciga-
rettes or sheesha (water pipe) within 1 month prior to
index admission. A positive family history of coronary
heart disease was defined as evidence of this disease in
a parent, sibling, or children before the age of 55 years.
The protocols of this study were approved by the Al
Ain Medical District Human Research Ethics Commit-
tee, Abu Dhabi and Dubai Health Authorities and the
Ministry of Health. All patients gave informed written
consent to participate and care was taken to ensure
data anonymity.
Statistical analysis
All data were analyzed with SPSS statistical software ver-
sion 19.0 (Chicago, Illinois, USA). The comparison of
continuous variables between patients with and without
HF was performed using the Student t-test. Categorical
variables were compared using the Pearson’s chi-square
test (or Fisher exact test for expected cells less than 5).
Continuous variables with (approximately) normal distri-
bution were expressed as mean± SD. Multivariable back-
ward stepwise logistic binary regression analysis was
performed to estimate adjusted odds ratios (OR) of the
potentially independent predictors (note: such predictors
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adjusted for the following baseline covariates: age, gen-
der, heart rate, smoking, DM, hypertension, hyperlipid-
emia, past revascularization including coronary artery
bypasses graft surgery (CABG) or percutaneous coronary
intervention (PCI) and prior coronary artery disease
(CAD) including angina or myocardial infarction (MI).
Similarly, the association between HF and in-hospital
mortality was examined using step-wise logistic regres-
sion models adjusting for the following covariates: age,
gender, heart rate, smoking, DM, hypertension, hyper-
lipidemia, past revascularization including CABG or
PCI and prior CAD including angina or MI. In all cases




The records of 1691 ACS patients represent the total
sample of this study. Among these, 356 patients (21.1%)
had HF at hospital admission. The clinical characteristics
of the study sample, by HF diagnosis at hospital admis-
sion are shown in table 1. The mean age of the cohort
was 52.5 ± 11.6 years. Patients with HF were significantly
older than patients without HF (57.8 ± 13 vs.
51.2 ± 10.8 years; P < 0.001), were less likely to be male
(34.3% among females vs. 19.2% among males; P < 0.001)
and less likely to smoke (38.2% vs. 50.3%; P < 0.001). Risk
factors for coronary artery disease were more common
in patients with HF as they were more often hyperten-
sive (64.3% vs. 43.9%), hyperlipidemic (49.4% vs. 31.8%)
and diabetic (51.1% vs. 36.2%) (P < 0.001 for all compari-
sons). Furthermore, the HF group included a signifi-
cantly higher number of patients with prior angina/MI
and past PCI/CABG (50% vs. 34.2%; P < 0.001, 18.8% vs.
14.1%; P = 0.018, respectively) compared to the non-HF
group. Patients with HF were slightly less likely to have
STEMI on admission, but the overall distribution of ad-
mission diagnoses was not statistically different between
HF and other patients. Patients with HF had a higher
heart rate on presentation versus those without HF
(97 ± 27.2 vs. 81.4 ± 19.8 beats/min; P < 0.001).
Medical management
Table 2 outlines medication use and in-hospital manage-
ment of the study patients. Compared with patients
without HF, the use of aspirin, beta-blockers, calcium
channel blockers, diuretics and subcutaneous insulin
was significantly lower among patients with HF during
their hospital treatment (Table 2). At discharge, the use
of beta-blockers, calcium channel blockers, statins,
nitrates, diuretics, antiarrythmic agents, digoxin and
warfarin was significantly higher among patients with
HF (Table 2). Moreover, Patients with HF were morelikely to undergo invasive cardiac procedures than
patients without HF.
Predictors of HF
Table 3 shows that the odds of HF increases by 3.4% per
year of age (OR= 1.034; 95% CI: 1.021-1.047; P < 0.001).
Furthermore, patients with a history of hyperlipidemia
were 1.5 times (OR= 1.539; 95% CI: 1.096-2.162;
P = 0.013) more likely to present with HF than those
without history of dyslipidemia. The risk of HF increased
by 2.7% (OR= 1.027; 95% CI: 1.021-1.034; P < 0.001), for
every 1-beat-per-minute increase in heart rate. Finally,
the model also showed that having diabetes mellitus
(DM) increased the risk of HF by 42% (OR= 1.425; 95%
CI: 1.047-1.938; P = 0.024).
Heart failure and adverse outcomes including in-hospital
mortality
Major bleed (n = 15) and stroke (n = 9) were rare out-
comes. Stroke was significantly associated with in-
hospital mortality, even after adjustment for HF
(P < 0.001). Table 4 indicates that HF was significantly
associated with in-hospital mortality (OR= 11.821; 95%
CI: 5.385-25.948; P < 0.001). The in-hospital mortality
rate for male patients was substantially lower than the
mortality rate for female patients (OR= 0.419; 95% CI:
0.195-0.902; P < 0.033; using stepwise (backward selec-
tion) logistic regression).
Discussion
The overall incidence of HF complicating ACS in our
study was 21% (less so in males which represented
87.6% of the study population). This rate of HF is lower
than reported in some previous studies of HF after AMI
[9,10] but similar to several other ones [11-13]. Since
there is no definitive diagnostic test for HF, these differ-
ences may well be due to varying definitions of HF
among studies, exclusion criteria or as in the present
study, inclusion of all patients with ACS, or could be
due to different delays in seeking care thereby not re-
ceiving timely diagnosis or optimal therapies. It was
observed that one in four ACS patients from six Middle
Eastern countries in the entire GULF RACE cohort had
HF [11]. In this study and using only the UAE data from
the GULF RACE, we observed that one in five patients
with ACS had HF during admission. This high rate of
HF patients with ACS could be due to the high preva-
lence of DM in the region [14,15]. There is an increasing
recognition that diabetic patients suffer from diabetic
cardiomyopathy, including AMI and HF, which was ori-
ginally described in 1972 on the basis of observations in
four diabetic patients who presented with HF without
evidence of hypertension, CAD, valvular or congenital
heart disease [16]. Not surprisingly DM was also
Table 1 Demographic and baseline characteristics of the studied acute coronary syndrome patients according to the
presence of HF (n =1691)
Variable HF Non-HF P-value
(n = 356) (n = 1335)
Age, mean± SD, years 57.8 ± 13.0 51.2 ± 10.8 < 0.001
Male 284 (79.8) 1197 (89.7) < 0.001
Hypertension 229 (64.3) 586 (43.9) < 0.001
Hyperlipidemia 176 (49.4) 425 (31.8) < 0.001
Diabetes mellitus 182 (51.1) 483 (36.2) < 0.001
Smoking 136 (38.2) 672 (50.3) < 0.001
Family history of CAD 39 (11.0) 221 (16.6) 0.008
Prior angina or MI 178 (50.0) 457 (34.2) < 0.001
Past PCI or CABG 67 (18.8) 188 (14.1) 0.030
ACS diagnosis: 0.66
STEMI 141 (39.6) 572 (42.9)
NSTEMI 81 (22.8) 302 (22.6)
UA 131 (36.8) 453 (33.9)
LBBB MI 3 (0.8) 8 (0.6)
Admission characteristics:
Killip class:
I - 1335 (100)
II 221 (62.0) -
III 102 (28.7) -
IV 33 (9.3) -
ST deviation 287 (80.8) 998 (749) 0.021
Heart rate, mean± SD, beats/min 97 ± 27.2 81.4 ± 19.8 < 0.001
Systolic blood pressure, mean± SD, mm Hg 145.7 ± 40.5 141.7 ± 27.9 0.028
Diastolic blood pressure, mean± SD, mm Hg 87.2 ± 23.7 85.6 ± 17.1 0.167
Laboratory investigations*:
Peak CPK, mean± SD, (U/l) 1269.9 ± 1930.5 1295.2 ± 1941.3 0.167
Peak CPK-MB, mean± SD, (U/l) 99.1 ± 157.9 96.4 ± 135 0.109
Peak troponin, mean± SD, (μg/l)† 19.2 ± 79.3 15.8 ± 55.9 0.581
Percent with LVEF≤ 40% 138/282 (49) 700/959 (73) < 0.001
*Values were log10 transformed to approximate normality for the independent sample t-test.
†Peak troponin I or T (depending on recruiting centre).
Figures in parentheses are percentages.
Abbreviations: HF heart failure, SD standard deviation, CAD coronary artery disease, MI myocardial infarction, PCI percutaneous coronary intervention, CABG
coronary artery bypass surgery, NSTEMI non-ST-segment elevation myocardial infarction, STEMI ST-elevation myocardial infarction, LBBB left bundle branch block,
UA unstable angina, CPK creatinine phosphokinase, CPK-MB creatine kinase-myocardial band isoenzyme.
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ology precludes definitive causal interpretations. Most
likely, because of the proinflammatory, and prothrombo-
tic states associated with DM, diabetic patients with
ACS are at high risk of subsequent cardiovascular events
with poorer outcome and higher mortality rates [17-19].
This study also shows that HF is a common complica-
tion associated with all forms of ACS. Patients with ACS
complicated by HF were more likely to die in the hos-
pital or experience other in-hospital complications suchas cardiogenic shock, infarction or stroke, although it is
unclear from our logistic regression analyses whether
this is because HF was the direct cause of in-hospital
death (and other complications) in our patients or just a
sign of substantial cardiac damage. Of note is that in-
hospital mortality in our study of HF patients was 7.3%,
which is relatively high. In-hospital mortality in large US
registries was about 4% [20,21], whereas in the European
registries it ranged from 3.8% (ESC-HF Pilot) to 6.7%
(EHFS II) and 7.1% (FINN-AKVA) [22-24]. There was a
Table 2 In-hospital and discharge management of the
studied ACS patients with and without HF (n= 1691)
HF Non-HF P-value
(n = 356) (n = 1335)
In-hospital medical treatment:
Aspirin 344 (96.6) 1328 (99.5) < 0.001
Clopidogrel 336 (94.4) 1290 (96.6) 0.061
IV HEP 48 (13.5) 204 (15.3) 0.451
LMW HEP 311 (87.4) 1154 (86.4) 0.726
GP 132 (37.1) 534 (40.0) 0.329
BB 156 (43.8) 995 (74.5) < 0.001
ACE 231 (64.9) 900 (67.4) 0.375
AIIRB 18 (5.1) 57 (4.3) 0.562
CCB 40 (11.2) 98 (7.3) 0.022
Statins 329 (92.4) 1268 (95) 0.068
Nitrates 268 (75.3) 934 (70.0) 0.056
Diuretics 242 (68.0) 158 (11.8) < 0.001
SQ INS 160 (44.9) 368 (27.6) < 0.001
IV INS 15 (4.2) 33 (2.5) 0.104
Discharge medical treatment:
Aspirin 321 (90.2) 1293 (97.0) < 0.001
Clopidogrel 290 (81.5) 1105 (82.8) 0.812
BB 258 (72.5) 1148 (86.0) < 0.001
ACE 252 (70.8) 999 (74.8) 0.193
AIIRB 30 (8.4) 84 (6.3) 0.151
CCB 43 (12.1) 90 (6.7) 0.001
Statins 320 (90.9) 1273 (95.4) 0.001
Nitrates 181 (51.0) 543 (40.7) < 0.001
Diuretics 208 (58.4) 142 (10.7) < 0.001
Antiarrythmic agents 21 (6.0) 14 (1.0) < 0.001
Digoxin 16 (4.5) 6 (0.4) < 0.001
Warfarin 15 (4.2) 15 (1.1) < 0.001
In-hospital procedures:
Echocardiography 260 (73.0) 846 (63.4) 0.001
PCI 9 (2.5) 13 (1.0) 0.025
IABP 10 (2.8) 11 (0.8) 0.006
In-hospital outcomes:
Death 26 (7.3) 8 (0.6) < 0.001
Cardiogenic shock 44 (12.4) 22 (1.7) < 0.001
Infarction 16 (4.5) 26 (2.0) 0.011
Stroke 5 (1.4) 4 (0.3) 0.023
Figures in parentheses are percentages.
Abbreviations: DM diabetes mellitus, IV HEP intravenous heparin, LMW HEP low
molecular weight heparin, GP glycoprotein IIb/IIIa inhibitors, BB beta-blockers,
ACE angiotensin-converting enzyme inhibitors, AIIRB angiotensin II receptor
blockers, CCB calcium channel blockers, SQ Insulin subcutaneous insulin, IV
Insulin intravenous insulin, PCI percutaneous coronary intervention, IABP
Intra-aortic balloon pump.
Table 3 Independent predictors of in-hospital HF using
multivariable logistic regression
Criteria OR In-hospital HF P
95% CI
Age 1.034 1.021-1.047 < 0.001
hyperlipidemia 1.539 1.096-2.162 0.013
Heart rate 1.027 1.021-1.034 < 0.001
Prior CAD 1.322 0.949-1.841 0.100
DM 1.425 1.047-1.938 0.024
Abbreviation: HF heart failure, OR odds ratio, CI confidence interval, CAD
coronary artery disease including angina or myocardial infarction (MI), DM
diabetes mellitus.
The variables that were dropped out of the multivariable logistic regression
using the stepwise-backward elimination method included gender, smoking,
hypertension and past revascularization (CABG/PCI).
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patients with HF. While the lower use of beta-blockers
may be explained by the difficulty of starting such the-
rapy early in patients with HF, the reason for the low rate
of cardiac catheterization in these patients is uncertain.
The strengths of this investigation include its national
perspective, the complete spectrum of ACSs experienced
by the large number of patients studied and the use of
standardized criteria for defining ACS and hospital out-
comes. However, as with any observational registry-type
study, the present findings have limitations. Although this
registry includes 18 hospitals throughout the UAE, partici-
pating sites may not be representative of the whole coun-
try. Furthermore, post admission variables analyses related
to physician discretion (medications, interventions) may
be strongly influenced by unmeasured confounders. Our
analysis is also limited by the lack of adequate follow up
data on long term mortality and morbidity and it is pos-
sible that some patients were misclassified according to
the Killip and Kimball [8] classification for signs of HF. Fi-
nally, the standard practice management of ACS in the
participating hospitals were initially, predominantly con-
servative. There were few PCI facility centers and hardly
any primary PCI center with an established interventionalTable 4 Relationship between HF and in-hospital
mortality using multivariable logistic regression
Criteria OR In-hospital mortality P
95% CI
HF 11.821 5.385-25.948 < 0.001
Gender 0.419 0.195-0.902 0.033
Heart rate 1.013 1.000-1.026 0.068
Abbreviation: HF heart failure, OR odds ratio, CI confidence interval.
The variables that were dropped out of the multivariable logistic regression
using the stepwise-backward elimination method included age, smoking,
diabetes mellitus, hypertension, hyperlipidemia, past revascularization
(CABG/PCI) and prior coronary artery disease (CAD) include angina or (MI).
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impact upon the incidence and severity of HF.
Conclusions
In conclusion, in this cohort of patients with ACS in the
UAE, HF complicates one-fifth of cases and was asso-
ciated with age, heart rate, hyperlipidemia and DM.
In-hospital mortality rate was associated with HF and
gender. Further studies are needed to better risk-stratify
patients with HF for more analysis as well as having in-
formation about prior history of HF and outcomes of
post-hospital discharge in order to optimize the use of
medications and cardiovascular interventions for this
serious condition.
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